Literature DB >> 18223023

Angiotensin-converting enzyme 2 and the kidney.

Maria Jose Soler1, Jan Wysocki, Daniel Batlle.   

Abstract

Angiotensin-converting enzyme (ACE) 2 is a homologue of ACE with enzymatic activity that seems to counterbalance the angiotensin II-promoting effect of ACE. While ACE promotes angiotensin (Ang) II formation from Ang I, ACE2 degrades Ang II and Ang I. In this review, we discuss recent studies that have delineated the localization of ACE2 within the kidney, an organ that highly expresses this enzyme. In models of diabetic kidney, pharmacological ACE2 inhibition is associated with albuminuria and worsening of glomerular injury. Similarly, genetic ablation of ACE2 causes glomerular lesions in male mice and worsens the renal lesions seen in diabetic Akita mice. Taken together, these findings suggest that a decrease in ACE2 may be involved in diabetic kidney disease, possibly by disrupting the metabolism of angiotensin peptides in such a way that angiotensin II degradation within the glomerulus may be diminished.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223023     DOI: 10.1113/expphysiol.2007.041350

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  19 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

2.  Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression.

Authors:  Er-Liang Kong; Jin-Min Zhang; Ni An; Yong Tao; Wei-Feng Yu; Fei-Xiang Wu
Journal:  J Cell Commun Signal       Date:  2018-06-07       Impact factor: 5.782

Review 3.  Diabetic kidney disease: from physiology to therapeutics.

Authors:  Carmen Mora-Fernández; Virginia Domínguez-Pimentel; Mercedes Muros de Fuentes; José L Górriz; Alberto Martínez-Castelao; Juan F Navarro-González
Journal:  J Physiol       Date:  2014-06-06       Impact factor: 5.182

4.  Angiotensin-converting enzyme 2 influences pancreatic and renal function in diabetic mice.

Authors:  María José Soler; Marta Riera; Heleia Roca-Ho; Vanesa Palau; Javier Gimeno; Julio Pascual
Journal:  Lab Invest       Date:  2020-05-29       Impact factor: 5.662

5.  Enzymatic processing of angiotensin peptides by human glomerular endothelial cells.

Authors:  Juan Carlos Q Velez; Jessalyn L Ierardi; Alison M Bland; Thomas A Morinelli; John M Arthur; John R Raymond; Michael G Janech
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-28

6.  Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse.

Authors:  Marta Riera; Eva Márquez; Sergi Clotet; Javier Gimeno; Heleia Roca-Ho; Josep Lloreta; Nuria Juanpere; Daniel Batlle; Julio Pascual; María José Soler
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

7.  Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse.

Authors:  Heleia Roca-Ho; Marta Riera; Vanesa Palau; Julio Pascual; Maria Jose Soler
Journal:  Int J Mol Sci       Date:  2017-03-05       Impact factor: 5.923

Review 8.  Worse progression of COVID-19 in men: Is testosterone a key factor?

Authors:  Vito A Giagulli; Edoardo Guastamacchia; Thea Magrone; Emilio Jirillo; Giuseppe Lisco; Giovanni De Pergola; Vincenzo Triggiani
Journal:  Andrology       Date:  2020-06-28       Impact factor: 4.456

9.  Single-cell RNA sequencing analysis of human kidney reveals the presence of ACE2 receptor: A potential pathway of COVID-19 infection.

Authors:  Qiyu He; Tsz N Mok; Liang Yun; Chengbo He; Jieruo Li; Jinghua Pan
Journal:  Mol Genet Genomic Med       Date:  2020-08-03       Impact factor: 2.183

Review 10.  Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.

Authors:  Giuseppe Lisco; Anna De Tullio; Vito Angelo Giagulli; Edoardo Guastamacchia; Giovanni De Pergola; Vincenzo Triggiani
Journal:  Endocrine       Date:  2020-08-10       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.